Navigation Links
ULURU Inc. Announces Appointment of Jeffrey A. Niezgoda, M.D., as Chairman of Scientific Advisory Board
Date:3/13/2009

ADDISON, Texas, March 13 /PRNewswire-FirstCall/ -- ULURU Inc. (NYSE Alternext: ULU) today announced the appointment of Jeffrey A. Niezgoda, MD, FACHM, FACEP, FAPWCA as Chairman of the Company's Scientific Advisory Board.

Currently, Dr. Jeffrey Niezgoda is the Medical Director of The Centers for Comprehensive Wound Care and Hyperbaric Oxygen Therapy, St. Luke's Medical Center, Aurora Health Care, in Milwaukee, Wisconsin. He also serves as the President and Chief Operating Officer of Hyperbaric & Wound Care Associates, a medical specialty group serving Southeastern Wisconsin and Northern Illinois, and as the President of the American College of Hyperbaric Medicine. Dr. Niezgoda is a nationally recognized wound care expert and has served as faculty at both national as well as international conferences. He has participated on multiple Expert Consensus Panels and has appeared before Medicare and Medicaid Services as a wound care consultant.

Renaat Van den Hooff, President & CEO of ULURU Inc. commented, "We are delighted that Dr. Niezgoda has accepted this important role with the Company. His extensive experience with Altrazeal(TM) has been invaluable and as Chairman of the Scientific Advisory Board, Dr. Niezgoda will help us to accelerate our clinical development and Altrazeal(TM) product development program."

Altrazeal(TM), a transforming powder dressing, is suitable for exuding wounds such as burns, abrasions, trauma, skin graft donor sites, surgical wounds, along with chronic, slow-healing wounds, such as diabetic foot ulcers and venous ulcers. Altrazeal(TM) is an innovative breakthrough, designed for greater effectiveness in wound closure by promoting an optimal moist wound healing environment, reducing pain, enhancing patient comfort, ease of application and removal and typically not requiring a secondary dressing.

Dr. Jeffrey A. Niezgoda stated, "I continue to be impressed with the positive clinical results achieved using Altrazeal(TM). This product offers the potential to significantly change the way healthcare providers approach the treatment of wounds and I am pleased to have the opportunity to contribute to accomplish that vision."

About ULURU Inc.:

ULURU Inc. is a specialty pharmaceutical company focused on the development of a portfolio of wound management and oral care products to provide patients and consumers improved clinical outcomes through controlled delivery utilizing its innovative transmucosal delivery system and Nanoflex(TM) Aggregate technology. For further information about ULURU Inc., please visit our website at www.uluruinc.com.

This press release contains certain statements that are forward-looking within the meaning of Section 27a of the Securities Act of 1933, as amended, including but not limited to statements made relating to the benefits, effectiveness, and suitability of Altrazeal(TM), and the success of our clinical efforts. These statements are subject to numerous risks and uncertainties, including but not limited to the risk factors detailed in the Company's Annual Report on Form 10-KSB for the year ended December 31, 2007 and quarterly report on Form 10-Q for the quarter ended September 30, 2008, and other reports filed by us with the Securities and Exchange Commission.

    Contact: Company
    Renaat Van den Hooff
    President & CEO
    Terry K. Wallberg
    Vice President & CFO
    (214) 905-5145


'/>"/>
SOURCE ULURU Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. ULURU Inc. to Present at UBS Global Life Sciences Conference 2007
2. ULURU Inc. Announces Odd-Lot Buy Back Offer
3. ULURU Inc. Announces Conference Call to Discuss Financial Results for the Third Quarter Ended September 30, 2007 and Provide a Business Update
4. ULURU Inc. Reports Third Quarter 2007 Results
5. ULURU Inc. Announces Issuance of Notice of Allowance for Nanoparticle Aggregate Patent
6. ULURU Inc. to Present at Cowen and Company 28th Annual Health Care Conference 2008
7. ULURU Inc. Announces Conference Call to Discuss Financial Results for the First Quarter Ended March 31, 2008 and Provide a Business Update
8. ULURU Inc. Announces Conference Call to Discuss Financial Results for the Fourth Quarter Ended December 31, 2007 and Provide a Business Update
9. ULURU Inc. Announces the Launch Plan for Altrazeal(TM)
10. ULURU Inc. Reports First Quarter 2008 Financial Results
11. ULURU Inc. Announces the Appointment of Ronald A. Ahrens to the Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/21/2017)... (PRWEB) , ... January 21, 2017 , ... ... of its new medical office in Petaluma, located at 167 Lynch Creek Way. ... access to SRO sports medicine and rehabilitation services and on-site x-ray ...
(Date:1/20/2017)... ... 20, 2017 , ... Spectrum Aquatics Launches New ADA Portable Motion Trek BP 300 Lift. Built ... is mounted on wheels, it can be wheeled out of the way and stored when ... the deck. "We have transformed the feedback from customers into specific enhancements and created a ...
(Date:1/20/2017)... ... January 20, 2017 , ... Source Vitál Apothecary, a skin and body ... oils, announced the company had a successful visit to the 2017 ECRM Diet, Vitamin ... companies that work in the nutritional, sports and health industries a chance to meet ...
(Date:1/20/2017)... ... January 20, 2017 , ... Lice Troopers, the lice removal company ... with school-aged children since the holiday season. , “It happens every year around ... sharing hugs and taking photos, which is the head-to-head gateway that lice need to ...
(Date:1/20/2017)... ... January 20, 2017 , ... Michael and Betsy Brauser celebrated 5 years ... Betsy, the clinical trial has been life-saving as she has been on the ... Betsy Brauser was diagnosed with ovarian cancer in 2009. She underwent standard chemotherapy but ...
Breaking Medicine News(10 mins):
(Date:1/20/2017)... , January 20, 2017 Avillion LLP, ... appointment of Mark Weinberg , MD MBA as Chief Medical ... , USA . ... Dr Weinberg has spent more than 17 years ... 20" pharma companies to micro-cap biotech. Over the course of his ...
(Date:1/19/2017)... YORK , Jan. 19, 2017 Report ... Ophthalmic Devices Market? Which areas are going to grow ... potential revenues to 2026, assessing data, trends, opportunities and ... and graphs. Discover the most lucrative areas in the ... lets you assess forecasted sales across the all the ...
(Date:1/19/2017)... 2017 Conference Call and Webcast to Follow ... it will release results for the fourth quarter of 2016 on ... ... call at 4:30 PM ET on Wednesday, February 15, 2017, during ... financial results and other corporate activities. To participate in the conference ...
Breaking Medicine Technology: